Chitosan-Gelatin Hydrogel Crosslinked With Oxidized Sucrose for the Ocular Delivery of Timolol Maleate

El-Feky, Gina S.; Zayed, Gamal; Elshaier, Yaseen A.M.M.; Alsharif, Fahd M.

doi:10.1016/j.xphs.2018.08.015

Cited by 54 publications

(36 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This could be attributed to the high swelling properties of CS-AAMPS (Figure 4) allowing the drug to be easily released, while the lowest swelling properties of CS hinder the release. These prolonged release findings are clearly in agreement with the reported literature using several nanoparticles [112] as well as chitosan-gelatin hydrogels, which showed promising mucoadhesive and in vitro release rates for a longer period of time for the timolol drug, compared to the conventional eye drops [114]. It seems that hydrogels may be ideal systems for extended and controlled release applications for CHL drug [115], and our prepared derivatives behave much alike.…”

Section: Drug Releasesupporting

confidence: 91%

See 1 more Smart Citation

Chitosan Derivatives with Mucoadhesive and Antimicrobial Properties for Simultaneous Nanoencapsulation and Extended Ocular Release Formulations of Dexamethasone and Chloramphenicol Drugs

et al. 2020

View full text Add to dashboard Cite

The aim of this work was to evaluate the effectiveness of neat chitosan (CS) and its derivatives with 2-acrylamido-2-methyl-1-propanesulfonic acid (AAMPS) and [2-(methacryloyloxy)ethyl]dimethyl-(3-sulfopropyl)ammonium hydroxide (MEDSP) as appropriate nanocarriers for the simultaneous ocular administration of dexamethasone sodium phosphate (DxP) and chloramphenicol (CHL). The derivatives CS-AAMPS and CS-MEDSP have been synthesized by free-radical polymerization and their structure has been proved by Fourier-Transformed Infrared Spectroscopy (FT-IR) spectroscopy. Both derivatives exhibited low cytotoxicity, enhanced mucoadhesive properties and antimicrobial activity against Staphylococcus aureus (S.aureus) and Escherichia coli (E. coli). Encapsulation was performed via ionic crosslinking gelation using sodium tripolyphosphate (TPP) as the crosslinking agent. Dynamic light scattering measurements (DLS) showed that the prepared nanoparticles had bimodal distribution and sizes ranging from 50–200 nm and 300–800 nm. Drugs were encapsulated in their crystalline (CHL) or amorphous (DexSP) form inside nanoparticles and their release rate was dependent on the used polymer. The CHL dissolution rate was substantially enhanced compared to the neat drug and the release time was extended up to 7 days. The release rate of DexSP was much faster than that of CHL and was prolonged up to 3 days. Drug release modeling unveiled that diffusion is the main release mechanism for both drugs. Both prepared derivatives and their drug-loaded nanoparticles could be used for extended and simultaneous ocular release formulations of DexSP and CHL drugs.

show abstract

Section: Drug Releasesupporting

confidence: 91%

“…drug, compared to the conventional eye drops [114]. It seems that hydrogels may be ideal systems for extended and controlled release applications for CHL drug [115], and our prepared derivatives behave much alike.…”

Section: Drug Releasementioning

confidence: 84%

Chitosan Derivatives with Mucoadhesive and Antimicrobial Properties for Simultaneous Nanoencapsulation and Extended Ocular Release Formulations of Dexamethasone and Chloramphenicol Drugs

et al. 2020

View full text Add to dashboard Cite

show abstract

“…El-Feky et al used oxidized sucrose as a crosslinking agent, which is expected to be less toxic than traditional crosslinking agents [251]. Sucrose is a disaccharide that is made of glucose and fructose.…”

Section: Proteinsmentioning

confidence: 99%

Chitosan and its Derivatives for Ocular Delivery Formulations: Recent Advances and Developments

et al. 2020

View full text Add to dashboard Cite

Chitosan (CS) is a hemi-synthetic cationic linear polysaccharide produced by the deacetylation of chitin. CS is non-toxic, highly biocompatible, and biodegradable, and it has a low immunogenicity. Additionally, CS has inherent antibacterial properties and a mucoadhesive character and can disrupt epithelial tight junctions, thus acting as a permeability enhancer. As such, CS and its derivatives are well-suited for the challenging field of ocular drug delivery. In the present review article, we will discuss the properties of CS that contribute to its successful application in ocular delivery before reviewing the latest advances in the use of CS for the development of novel ophthalmic delivery systems. Colloidal nanocarriers (nanoparticles, micelles, liposomes) will be presented, followed by CS gels and lenses and ocular inserts. Finally, instances of CS coatings, aiming at conferring mucoadhesiveness to other matrixes, will be presented.

show abstract

“…The prepared nanoformulations showed a controlled release of drug up to 12 h and potent antibacterial activity against Staphylococcus aureus and Bacillus subtilis. The use of hybrid systems based on gelatin was also suggested for effective ocular topical administration of drugs [92]; gelatin nanoparticles loaded with timolol maleate were successfully included in a hydroxypropyl methylcellulose (HPMC) carrier with the aim of reducing the high IOP in glaucoma [93]. In another work, mesoporous silica nanoparticles were covered by pilocarpine-loaded gelatin (p/GM) and intracamerally injected into the anterior chamber of rabbit eyes to extend the drug release time, improve ocular bioavailability, and reduce the IOP (Figure 3) [94].…”

Section: Gelatinmentioning

confidence: 99%

Regulation of the Ocular Cell/Tissue Response by Implantable Biomaterials and Drug Delivery Systems

Baino

Kargozar

2020

Bioengineering

View full text Add to dashboard Cite

Therapeutic advancements in the treatment of various ocular diseases is often linked to the development of efficient drug delivery systems (DDSs), which would allow a sustained release while maintaining therapeutic drug levels in the target tissues. In this way, ocular tissue/cell response can be properly modulated and designed in order to produce a therapeutic effect. An ideal ocular DDS should encapsulate and release the appropriate drug concentration to the target tissue (therapeutic but non-toxic level) while preserving drug functionality. Furthermore, a constant release is usually preferred, keeping the initial burst to a minimum. Different materials are used, modified, and combined in order to achieve a sustained drug release in both the anterior and posterior segments of the eye. After giving a picture of the different strategies adopted for ocular drug release, this review article provides an overview of the biomaterials that are used as drug carriers in the eye, including micro- and nanospheres, liposomes, hydrogels, and multi-material implants; the advantages and limitations of these DDSs are discussed in reference to the major ocular applications.

show abstract

Chitosan-Gelatin Hydrogel Crosslinked With Oxidized Sucrose for the Ocular Delivery of Timolol Maleate

Cited by 54 publications

References 39 publications

Chitosan Derivatives with Mucoadhesive and Antimicrobial Properties for Simultaneous Nanoencapsulation and Extended Ocular Release Formulations of Dexamethasone and Chloramphenicol Drugs

Chitosan Derivatives with Mucoadhesive and Antimicrobial Properties for Simultaneous Nanoencapsulation and Extended Ocular Release Formulations of Dexamethasone and Chloramphenicol Drugs

Chitosan and its Derivatives for Ocular Delivery Formulations: Recent Advances and Developments

Regulation of the Ocular Cell/Tissue Response by Implantable Biomaterials and Drug Delivery Systems

Contact Info

Product

Resources

About